Neural Mechanisms Underlying Alcohol Induced Disinhibition
NCT ID: NCT01097213
Last Updated: 2013-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2010-12-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration
NCT04971681
Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge
NCT01969617
Exploring Regulation and Function of Dopamine D3 Receptors in Alcohol Use Disorders: A [11C]-(+)-PHNO Study
NCT03037060
Alcohol, Behavior, and Brain Imaging
NCT03930446
Neurofeedback & Alcohol Dependence
NCT02486900
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ethanol
Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
Placebo - half-normal saline
Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* written informed consent by the subject;
* habitual social drinking during the two months preceding participation, defined by at least one drinking day in any two weeks-interval;
* at least one prior experience of alcohol intoxication
* being able to abstain from tobacco use for four hours without developing nicotine withdrawal symptoms;
* effective contraception in female participants;
* consenting to abstain from any illegal substance use for 2 weeks prior to participation;
* living within 15 km (9.5 miles) from downtown Dresden;
* sufficient information concerning alcohol use in both parents and in at least four second-degree relatives
Exclusion Criteria
* current or prior history of any serious disease, including CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, alcohol or drug dependence, but not alcohol abuse;
* current history of Axis-I psychiatric illness, including premenstrual dysphoric disorder;
* current or prior history of alcohol-induced flushing reactions;
* positive urine screen for cannabinoids, cocaine, amphetamines, opiates, or benzodiazepines;
* light or non-drinkers: averaging less than 2 standard drinks per week in the preceding two months;
* intention to become pregnant
* pregnancy or positive urine pregnancy screening or breast-feeding;
* any alcohol intake on the test day or the day before;
* use of medications known to interact with alcohol within 2 weeks of the study;
* positive hepatitis or HIV at screening, provided the subject consented to these tests
* any conditions posing safety issues with the fMRI scan, such as ferromagnetic implants, cardiac pacemakers or insulin pumps
18 Years
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University School of Medicine
OTHER
Technische Universität Dresden
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael N. Smolka, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Technische Universitaet Dresden - - Faculty of Medicine Carl Gustav Carus - Department of Psychiatry and Psychotherapy
Ulrich S. Zimmermann, Dr.
Role: PRINCIPAL_INVESTIGATOR
Universitaetsklinikum Carl Gustav Carus at the Technische Universitaet Dresden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Technische Universitaet Dresden - Dresden fMRT-Neuroimaging Center
Dresden, Saxony, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gan G, Guevara A, Marxen M, Neumann M, Junger E, Kobiella A, Mennigen E, Pilhatsch M, Schwarz D, Zimmermann US, Smolka MN. Alcohol-induced impairment of inhibitory control is linked to attenuated brain responses in right fronto-temporal cortex. Biol Psychiatry. 2014 Nov 1;76(9):698-707. doi: 10.1016/j.biopsych.2013.12.017. Epub 2014 Jan 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U01 AA017900 SA2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.